Daiichi Sankyo Now Authorized to Market Its Products in China.Tokyo, Japan, June 20, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Daiichi Sankyo has announced that its subsidiary Sankyo's affiliate in China, Shanghai Shanghai (shăng`hī`, shäng`hī`), city (1994 est. pop. 12,980,000), in, but independent of, Jiangsu prov., E China, on the Huangpu (Whangpoo) River where it flows into the Chang (Yangtze) estuary. Sankyo Pharmaceuticals, has obtained a medicine management certificate. With this approval, Shanghai Sankyo Pharmaceuticals can import and distribute finished products from its parent company Sankyo (as well as Daiichi Sankyo in the future) in China. As an initial step, Shanghai Sankyo Pharmaceuticals plans to import and sell antitumor an·ti·tu·mor also an·ti·tu·mor·al adj. Counteracting or preventing the formation of malignant tumors; anticancer. Adj. 1. agent Nidran from mid- mid- pref. Middle: midbrain. 2006. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion